Low doses of cps49 and flavopiridol combination as potential treatment for advanced prostate cancer

Florencia Zalazar; Paola De Luca; Kevin Gardner; William D. Figg; Roberto Meiss; Raúl G. Spallanzani; Pablo Vallecorsa; Belén Elguero; Javier Cotignola; Elba Vazquez; Adriana De Siervi

doi:10.2174/138920102012190919103433

Low doses of cps49 and flavopiridol combination as potential treatment for advanced prostate cancer

Florencia Zalazar, Paola De Luca, Kevin Gardner, William D. Figg, Roberto Meiss, Raúl G. Spallanzani, Pablo Vallecorsa, Belén Elguero, Javier Cotignola, Elba Vazquez, Adriana De Siervi^*

^*Corresponding author for this work

Research output: Contribution to journal › Comment/debate

Abstract

Due to some inconsistencies in the figures provided by the first author that have come to light, and after a thorough investigation we would like to retract our paper: “Low doses of CPS49 and flavopiridol combination as potential treatment for advanced prostate cancer. By: Zalazar F, De Luca P, Gardner K, Figg WD, Meiss R, Spallanzani RG, Vallecorsa P, Elguero B, Cotignola J, Vazquez E, De Siervi A. Curr. Pharm. Biotechnol., 2015, 16(6), 553-63. Submission of a manuscript to the respective journals implies that all authors have read and agreed to the content of the Copyright Letter or the Terms and Conditions. As such this article represents a severe abuse of the scientific publishing system. Bentham Science Publishers takes a very strong view on this matter and apologizes to the readers of the journal for any inconvenience this may cause.

Original language	English
Pages (from-to)	1072
Number of pages	1
Journal	Current Pharmaceutical Biotechnology
Volume	20
Issue number	12
DOIs	https://doi.org/10.2174/138920102012190919103433
State	Published - 2019
Externally published	Yes

Access to Document

10.2174/138920102012190919103433

Cite this

@article{c8c022b73333405aac9c3752bc022cd3,

title = "Low doses of cps49 and flavopiridol combination as potential treatment for advanced prostate cancer",

abstract = "Due to some inconsistencies in the figures provided by the first author that have come to light, and after a thorough investigation we would like to retract our paper: “Low doses of CPS49 and flavopiridol combination as potential treatment for advanced prostate cancer. By: Zalazar F, De Luca P, Gardner K, Figg WD, Meiss R, Spallanzani RG, Vallecorsa P, Elguero B, Cotignola J, Vazquez E, De Siervi A. Curr. Pharm. Biotechnol., 2015, 16(6), 553-63. Submission of a manuscript to the respective journals implies that all authors have read and agreed to the content of the Copyright Letter or the Terms and Conditions. As such this article represents a severe abuse of the scientific publishing system. Bentham Science Publishers takes a very strong view on this matter and apologizes to the readers of the journal for any inconvenience this may cause.",

author = "Florencia Zalazar and {De Luca}, Paola and Kevin Gardner and Figg, {William D.} and Roberto Meiss and Spallanzani, {Ra{\'u}l G.} and Pablo Vallecorsa and Bel{\'e}n Elguero and Javier Cotignola and Elba Vazquez and {De Siervi}, Adriana",

note = "Publisher Copyright: {\textcopyright} 2019 Bentham Science Publishers.",

year = "2019",

doi = "10.2174/138920102012190919103433",

language = "English",

volume = "20",

pages = "1072",

journal = "Current Pharmaceutical Biotechnology",

issn = "1389-2010",

number = "12",

}

TY - JOUR

T1 - Low doses of cps49 and flavopiridol combination as potential treatment for advanced prostate cancer

AU - Zalazar, Florencia

AU - De Luca, Paola

AU - Gardner, Kevin

AU - Figg, William D.

AU - Meiss, Roberto

AU - Spallanzani, Raúl G.

AU - Vallecorsa, Pablo

AU - Elguero, Belén

AU - Cotignola, Javier

AU - Vazquez, Elba

AU - De Siervi, Adriana

PY - 2019

Y1 - 2019

N2 - Due to some inconsistencies in the figures provided by the first author that have come to light, and after a thorough investigation we would like to retract our paper: “Low doses of CPS49 and flavopiridol combination as potential treatment for advanced prostate cancer. By: Zalazar F, De Luca P, Gardner K, Figg WD, Meiss R, Spallanzani RG, Vallecorsa P, Elguero B, Cotignola J, Vazquez E, De Siervi A. Curr. Pharm. Biotechnol., 2015, 16(6), 553-63. Submission of a manuscript to the respective journals implies that all authors have read and agreed to the content of the Copyright Letter or the Terms and Conditions. As such this article represents a severe abuse of the scientific publishing system. Bentham Science Publishers takes a very strong view on this matter and apologizes to the readers of the journal for any inconvenience this may cause.

AB - Due to some inconsistencies in the figures provided by the first author that have come to light, and after a thorough investigation we would like to retract our paper: “Low doses of CPS49 and flavopiridol combination as potential treatment for advanced prostate cancer. By: Zalazar F, De Luca P, Gardner K, Figg WD, Meiss R, Spallanzani RG, Vallecorsa P, Elguero B, Cotignola J, Vazquez E, De Siervi A. Curr. Pharm. Biotechnol., 2015, 16(6), 553-63. Submission of a manuscript to the respective journals implies that all authors have read and agreed to the content of the Copyright Letter or the Terms and Conditions. As such this article represents a severe abuse of the scientific publishing system. Bentham Science Publishers takes a very strong view on this matter and apologizes to the readers of the journal for any inconvenience this may cause.

UR - http://www.scopus.com/inward/record.url?scp=85074729117&partnerID=8YFLogxK

U2 - 10.2174/138920102012190919103433

DO - 10.2174/138920102012190919103433

M3 - Comment/debate

C2 - 31701844

AN - SCOPUS:85074729117

SN - 1389-2010

VL - 20

SP - 1072

JO - Current Pharmaceutical Biotechnology

JF - Current Pharmaceutical Biotechnology

IS - 12

ER -

Low doses of cps49 and flavopiridol combination as potential treatment for advanced prostate cancer

Abstract

Access to Document

Fingerprint

Cite this